BAYRYBayer AG (ADR)

$10.44
$0.04
(0.39%)
Today
Updated: 04:00 PM EDT
EarningsAug 4
Mkt Cap$41.03B
Vol614,627.00
News
all
press releases
Novartis Reports Positive Data for Neuromuscular Disorder Drug
NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying treatment for FSHD.
Zacks
News Placeholder
More News
News Placeholder
EMA Begins Review of Bayer's Asundexian Filing for Stroke Prevention
BAYRY's asundexian enters EMA review for stroke prevention after phase III data showed a 26% cut in ischemic stroke without more major bleeding.
Zacks
News Placeholder
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
Zacks
News Placeholder
Here's Why Investors Must Hold IQV Stock in Their Portfolios for Now
IQVIA's record $34.2B backlog, AI-led pharma demand and $1.24B buybacks support growth despite weak liquidity and no dividend.
Zacks
News Placeholder
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk and Bayer
Eli Lilly, Johnson & Johnson, Novo Nordisk and Bayer are benefiting from innovation, pipeline growth and strong demand in key therapies.
Zacks
News Placeholder
4 Large-Cap Pharma Stocks to Buy as Industry Recovery Accelerates
In the Large-Cap Pharmaceuticals industry, LLY, J&J, NVO and BAYRY are worth retaining as the industry shows some recovery.
Zacks
News Placeholder
BAYRY's Kerendia Label Expansion Application Gets Priority Review
Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.
Zacks
News Placeholder
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Regeneron & Parabilis Sign Oncology Collaboration Worth Up to $2.2B
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
Zacks
<
1
2
...
>

Advertisement|Remove ads.